Neotherapeutics Form 8-K
Table of Contents

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES AND EXCHANGE ACT OF 1934

June 11, 2001
Date of Report (Date of earliest event reported)


NEOTHERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

         
Delaware
(State or other Jurisdiction
of Incorporation)
000-28782
(Commission File Number)
93-0979187
(IRS Employer
Identification Number)
 
157 Technology Drive
Irvine, California

(Address of principal executive offices)
92618
(Zip Code)

(949) 788-6700
(Registrant’s telephone number, including area code)

N/A
(Former Name or Former Address, if Changed Since Last Report)

 


TABLE OF CONTENTS

Item 7. Exhibits
Item 9. Regulation FD Disclosure
SIGNATURES
EXHIBIT INDEX
ex-99.1


Table of Contents

Item 7. Exhibits

Exhibits:

  99.1   Press Release dated June 11, 2001.

Item 9. Regulation FD Disclosure

On June 11, 2001, NeoTherapeutics, Inc. issued a news release regarding its publicly traded warrants, the text of which is set forth in Exhibit 99.1 attached to this report. Exhibit 99.1 is incorporated by reference into this report. NeoTherapeutics, Inc. is furnishing the information contained in this Current Report on Form 8-K pursuant to the Securities and Exchange Commission’s Regulation FD.

 


Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     
NEOTHERAPEUTICS, INC.
 
 
 
Date:    June 11, 2001 By:  /s/ Samuel Gulko

Name:     Samuel Gulko
Title: Chief Financial Officer

 


Table of Contents

EXHIBIT INDEX

Exhibits:

  99.1   Press Release dated June 11, 2001.